SBFM$2.82+2.55%
Sunshine Biopharma Inc.
Sector: Pharmaceutical PreparationsIndustry: Drug Manufacturers - Specialty & GenericCountry: USExchange: Nasdaq
Mkt Cap:$2.15M
Float & O/S:
Inst Own:
DilutionScan read 35 of Sunshine Biopharma Inc.'s SEC filings and found 7 warrant series, 1 convertible, 1 ATM program, 1 shelf registration, 4 S-1 registrations and 2 completed offerings on file for SBFM. The latest dilution event on file is an offering on Oct 9, 2026. Analysis updated Oct 26, 2026.
Signal8 Summary
SBFM
Severe dilution and delisting risk
Snapshot
Sunshine Biopharma is a tiny generic-drug and oncology-research company with $36.3M in FY 2025 revenue, up 4.1% YoY, and a 32.8% gross margin, but it lost $6.0M for the year and burned $5.5M in free cash flow.
What's Happening Right Now
- : Sunshine Biopharma filed an S-1 for a $7.0M offering plus new warrants, which would take shares outstanding from 4.3M to over 14.5M, with tens of millions more shares possible from existing warrants.
- : Sold $2.23M net / 1.86M shares through its at-the-market program, as stated for Jul 27, 2026 to Oct 2, 2026.
- : Registered 10.18M shares for sale on Form S-1.
- : CEO Steve Slilaty, who holds about 97% of voting power, approved a second reverse split (up to 1-for-20) within a year to try to fix Nasdaq's minimum bid-price compliance.
- : Sunshine Biopharma launched generic ondansetron (Zofran equivalent) tablets in Canada through its Nora Pharma distribution network, adding to its generic drug portfolio.
- : A new prospectus registers 25.5M shares tied to Series B Warrants with a downward-resetting strike price, alongside disclosure of three reverse splits since April 2024 and ongoing delisting exposure.
- : Registered 25.48M shares for sale on Form S-1.
- : The company agreed to pay about US$1.06 million to settle a dispute with Nora Pharma's former president over a 2022 acquisition and termination claims.
